Sign In
Buy HRTX
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
04:05pm, Thursday, 28'th Mar 2024
SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
10:35pm, Tuesday, 12'th Mar 2024
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
07:00pm, Tuesday, 12'th Mar 2024
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare wit
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
04:05pm, Tuesday, 12'th Mar 2024
2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance ZYNRELEF® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash eq
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:16am, Thursday, 07'th Mar 2024
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its
5 Small Drug Stocks to Buy From a Rebounding Industry
09:56am, Thursday, 29'th Feb 2024
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Heron Therapeutics Is Out Of Survival Mode
01:54am, Saturday, 17'th Feb 2024
Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 06'th Feb 2024
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
07:46am, Thursday, 25'th Jan 2024
Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.
– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage
The 3 Most Undervalued Biotech Stocks to Buy in January
04:51pm, Monday, 15'th Jan 2024
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech
Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy?
11:17am, Monday, 15'th Jan 2024
Heron Therapeutics, Inc. (HRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HRTX's 50-day simple moving average broke out above
Heron Therapeutics Gets Back On Track
03:14pm, Friday, 29'th Dec 2023
HRTX's Zynrelef sales are back on track, with potential for significant growth pending approval of a supplemental New Drug Application. Aponvie sales have been underwhelming thus far and probably won'
Why Heron Therapeutics Is A Compelling Buy Into 2024
09:00am, Thursday, 30'th Nov 2023
Heron Therapeutics develops solutions for pain and discomfort associated with chemotherapy and surgery, with four FDA-approved products. The company underwent a leadership change and implemented a pla
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
07:33pm, Tuesday, 28'th Nov 2023
Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market ac
